title: Pharmacotherapy of hepatocellular carcinoma.
abstract: Hepatocellular carcinoma (HCC) is one of the more common causes of cancer death worldwide. It occurs on a background of chronic liver disease or viral hepatitis in the vast majority of cases, with hepatitis C being mostly responsible for its continuing rise in western countries. With the screening of at-risk groups, up to 70% of HCC lesions will be detected at a treatable stage but at best, only 20-30% will benefit from potentially curative hepatic resection or transplantation. How best to treat the remaining nonsurgical patients is an area of much debate and no ideal treatment is yet available. This review summarises some of the therapeutic modalities used for HCC, with an emphasis on pharmacological therapies.
authors.affiliation: AW Morrow Gastroenterology and Liver Centre, Royal Prince Alfred Hospital, Missenden Rd, Camperdown 2050, Australia.
authors.forename: John F
authors.initials: JF
authors.lastname: Perry
authors.forename: Simone I
authors.initials: SI
authors.lastname: Strasser
authors.forename: Jacob
authors.initials: J
authors.lastname: George
authors.forename: Geoffrey C
authors.initials: GC
authors.lastname: Farrell
authors.forename: Geoffrey W
authors.initials: GW
authors.lastname: McCaughan
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D006801:Humans; D007269:Injections, Intra-Arterial; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000532:radiotherapy / Q000601:surgery; D020360:Neoadjuvant Therapy
chemical_list: D000970:Antineoplastic Agents